Frazier Life Sciences Management, L.P.
Annual return '25
+72.2%
SPY '25
+17.7%
Alpha
+54.5ptsvs SPY
Invested
$3.9B
Holdings
37
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 85%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$MIRM
MIRUM PHARMACEUTICALS INC
Held since at least Q1 2024
18.3%
02
$NAMS
NEWAMSTERDAM PHARMA COMPANY
Held since at least Q1 2024
14.0%
03
$ERAS
ERASCA INC
Held since at least Q1 2024
10.3%
04
$BBIO
BRIDGEBIO PHARMA INC
Held since at least Q1 2024
6.6%
05
$ARQT
ARCUTIS BIOTHERAPEUTICS INC
Held since at least Q1 2024
6.0%
06
$MBX
MBX BIOSCIENCES INC
Held since at least Q1 2024
5.1%
07
$PHAT
PHATHOM PHARMACEUTICALS INC
Held since at least Q1 2024
3.6%
08
$MAZE
MAZE THERAPEUTICS INC
Held since at least Q1 2024
3.5%
09
$KRYS
KRYSTAL BIOTECH INC
Held since at least Q1 2024
3.2%
10
$TRVI
TREVI THERAPEUTICS INC
Held since at least Q1 2024
3.1%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 09:24 UTC.